Investor Presentation Q1 2022
Commercial
execution
Purpose and
sustainability
(ESG)
4
Investor presentation
First three months of 2022
Progress towards zero environmental impact:
Strategic Aspirations 2025 | Highlights first three months 2022
•
Carbon emissions increased by 46% vs first quarter of
2021 and decreased 25% vs first quarter of 2019
Adding value to society:
Positive scientific opinion from EMA on human insulin
with more flexible storage option without refrigeration
Two months' supply of diabetes and haemophilia
medication donated to the Ukrainian Ministry of Health
Being recognised as a sustainable employer:
Share of females in senior leadership positions has
increased to 37% from 35% in the first quarter of 2021
Diabetes value market share increased by 1.2
percentage point to 30.5%¹
Obesity care sales increased by 107% at CER
to DKK 3.4 billion
Rare disease sales increased by 3% at CER
to DKK 5.4 billion
1 MAT (Moving annual total) value market share. IO: International Operations
The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Financials
therapeutic focus
Innovation and
.
Further raise innovation bar for Diabetes treatment:
Approval of OzempicⓇ 2.0 mg in the US
Successful completion of first phase 3 trial with once-
weekly insulin icodec
Phase 1 trial with Ideal Pump insulin successfully
completed
Phase 1 initiated with a once-daily oral GLP-1/GIP agonist
Strengthen and progress Rare disease pipeline
Concizumab phase 3 trial successfully completed in
people with haemophilia A and B with inhibitors
Sales growth of 18% and Operating profit growth of
18%:
.
Sales in International Operations grew by 13%
Sales in the US grew by 23% with 67% of sales coming
from products launched since 2015
Gross margin positively impacted by continued
productivity gains in Product Supply
Free cash flow of DKK 21.6 billion and DKK 20 billion
returned to shareholders during first quarter
Novo Nordisk®View entire presentation